Long-term survival of a patient with amyotrophic lateral sclerosis (ALS) who received autologous adipose-derived mesenchymal stem cells.
Shigematsu K., Takeda T., Komori N., Urushihata N., Oki K., Tahara K.
Case Report / Series on Neuroinflammation, published in Eur Rev Med Pharmacol Sci (2021) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Case Report / Series
- Journal
- Eur Rev Med Pharmacol Sci (2021)
- Country
- Italy
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 34156687
- DOI
- 10.26355/eurrev_202106_26050
- Citations
- 7
Abstract (original English)
Objective Amyotrophic lateral sclerosis (ALS) is a progressive debilitating neurodegenerative disease with a life expectancy of 3-5 years from initial symptoms. We report a case of ALS who received autologous adipose-derived mesenchymal stem cells (ADSC) and was followed up for 7 years. Case report A 46-year-old man noticed weakness of his legs, difficulties on going down the stairs and coughing during eating in 2009. After complete workout, a diagnosis of ALS was confirmed. His ALS Functional Rating Scale-R (ALSFS-R) was 43. Symptoms rapidly progressed and he coughed and choked during eating. Starting in 2013, the patient received a total of six intravenous infusions of autologous ADSC. Changes in electromyogram, nerve conduction, and ALSFS-R were assessed. Results Soon after the administration, he noticed that he did not cough during conversation or eating food. Although he had difficulty in walking down the stairs, he remained well without coughing, dysarthria, or dysphagia. His ALSFS-R increased up to 45. Fascicular potentials were not detected in any muscles examined including trapezius muscle and rectus femoris muscles. The patient was well for 7 years after ADSC therapy by the time of this report and more than 10 years from the time of onset. Conclusions The present case suggests that autologous ADSC can be administered safely and may be potentially useful in patients wi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level ASystematic ReviewEurope PMC
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
Systematic Review on Neuroinflammation, Skin Aging, published in Cureus (2026) — summary generated from the PubMed abstract.
- 2026
Cureus - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level ASystematic ReviewEurope PMC
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Systematic Review with a reported sample of 123 on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Biologics (2026) — summary generated from the PubMed abstract.
- 2026
- n = 123
Biologics